Showing 5261-5270 of 8786 results for "".
- MedPharm Ltd. Expands Partnership with Palvella Therapeutics, Inc. for PC Treatmenthttps://practicaldermatology.com/news/medpharm-ltd-expands-partnership-with-palvella-therapeutics-inc-for-pc-treatment/2459906/MedPharm Ltd, is expanding its partnership with Palvella Therapeutics, Inc. MedPharm has employed its formulation expertise to support Palvella’s development of a novel,
- New from BD: Prefillable Glass Syringe for Viscous Solutionshttps://practicaldermatology.com/news/new-from-bd-prefillable-glass-syringe-for-viscous-solutions/2459910/BD (Becton, Dickinson and Company) has presented BD Hylok,its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Pharmapack 2019. BD Hylokis also the first glass pre-fillab
- Study Finds Lack of Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizationshttps://practicaldermatology.com/news/study-finds-lack-of-disclosure-of-potential-conflicts-of-interest-in-dermatology-patient-advocacy-organizations/2459912/A recent study published in JAMA Dermatology was conducted to examine potential financial conflicts of interest and characterize disclosure practices among dermatology patient advocacy organizations. For this cross-sectional study of the largest dermatology patient ad
- Biologics May Reduce Plaque Buildup in Psoriasis Patients' Arterieshttps://practicaldermatology.com/news/biologics-may-reduce-plaque-buildup-in-psoriasis-patients-arteries/2459913/Treating psoriasis with biologic drugs can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, according to a study funded by the Natio
- Vyome Secures $22M to Advance Dermatology Pipelinehttps://practicaldermatology.com/news/vyome-secures-22m-to-advance-dermatology-pipeline/2459918/Vyome Therapeutics Inc., a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, closed $22 million in financing. The company says it plans to primarily use the funds to advance its lead molecule, VB 19
- Menlo Therapeutics to Present Late-Breaking Oral Presentation at AAD Annual Meetinghttps://practicaldermatology.com/news/menlo-therapeutics-to-present-late-breaking-oral-presentation-at-aad-annual-meeting/2459917/Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, DC. The ab
- Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/encore-dermatology-shares-positive-pivotal-study-results-for-impoyz-for-the-treatment-of-plaque-psoriasis/2459920/Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Trea
- Merz and Christie Brinkley Partner to Launch “Milestones of Me” Campaignhttps://practicaldermatology.com/news/merz-and-christie-brinkley-partner-to-launch-milestones-of-me-campaign/2459922/Merz Americas is partnering with supermodel, actress, and entrepreneur, Christie Brinkley, to launch its “Milestones of Me” campaign, which encourages women to celebrate the moments, big or small, that have made them who they are today. The campaign, which kicks off in honor of Christ
- New Data Show Cosentyx Improves Quality of Life in Patients Being Treated for Psoriasishttps://practicaldermatology.com/news/new-data-show-cosentyx-improves-quality-of-life-in-patients-being-treated-for-psoriasis/2459924/Novartis shared results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate to severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnair
- Alan Menter, MD Receives Outstanding Researcher and Educator in Psoriatic Disease Award from ODAC, JDDhttps://practicaldermatology.com/news/alan-menter-md-receives-outstanding-researcher-and-educator-in-psoriatic-disease-award-from-odacjdd/2459929/Alan Menter, MD, has been awarded the Outstanding Researcher and Educator in Psoriatic Disease Award by the ODAC Dermatology, Aesthetics & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD). The award recognizes Dr. Menter’